Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 11/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.42 |
| ▸ | WNT3A | P56704 | 2/20 | 0.42 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4922360 | 1.00 | DGAT1 (0.43) | DGAT1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4922361 | 1.00 | DGAT1 (0.43) | DGAT1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4924500 | 0.88 | DGAT1 (0.52) | DGAT1WNT3AMEN1KMT2ALMNA | |
| SCHEMBL4924505 | 0.88 | DGAT1 (0.52) | DGAT1WNT3AMEN1KMT2ALMNA | |
| SCHEMBL4924495 | 0.88 | DGAT1 (0.52) | DGAT1WNT3AMEN1KMT2ALMNA | |
| SCHEMBL4916334 | 0.84 | RAB9A (0.45) | DGAT1KMT2ALMNARAB9A | |
| SCHEMBL4925511 | 0.84 | HRH3 (0.49) | DGAT1WNT3APORCNROCK2LMNA | |
| SCHEMBL4916321 | 0.84 | RAB9A (0.45) | DGAT1KMT2ALMNARAB9A | |
| SCHEMBL4925525 | 0.84 | HRH3 (0.49) | DGAT1WNT3APORCNROCK2LMNA | |
| SCHEMBL4916306 | 0.84 | RAB9A (0.45) | DGAT1KMT2ALMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064717-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES | 2008-03-13 | — | — | US | claimed |
| US-20080064717-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064717-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | DGAT1, DGAT2, DLAT | DGAT1 1/4885PSEN1 2377/4885PSEN2 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.